DOBU produces paresthesia and difficulty sleeping, but with few other effects. Compared to shorter chain homologues such as DOM, DOET and DOPR which are all potent hallucinogens, DOBU has an even stronger 5-HT2 binding affinity but fails to substitute for hallucinogens in animals or produce hallucinogenic effects in humans, suggesting it has low efficacy and is thus an antagonist or weak partial agonist at the 5-HT2A receptor.
DOBU causes paresthesia and sleep disturbances but has few other effects. Compared to shorter-chain homologues such as DOM, DOET, and DOPR, which are potent hallucinogens, DOBU exhibits a stronger affinity for 5-HT2 receptors without being effective in animals or humans, suggesting it may act as an antagonist or weak partial agonist at the 5-HT2A receptor.